2020 compared to $1.3 million for the three months ended September 30, 2019. The decrease in 2020 was due to a decrease in net accretion income and a decrease in interest income resulting from a lower yield on the Company’s lower average balance of its portfolio of investments in the...
21, 202213 Comments Cara Therapeutics: De-Risked And Extremely AttractiveAquarius ResearchSat, Dec. 25, 202123 Comments Checking Back In On Cara TherapeuticsBret JensenMon, Nov. 01, 20212 Comments Share your Analysis on CARASubmit an article now See All Analysis » CARA News...